Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Companies Come Up With Creative Solutions To Increase Access To Rural Communities In Asia

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - A little less than two years ago, multinational conglomerate GE Healthcare said it would spend up to $6 billion in healthcare innovation through a program dubbed "Healthymagination.

You may also be interested in...



A Closer Look: Changes To China’s Orthopedics Market Fuel Deals Like Stryker-Trauson

Large domestic players like Trauson could benefit from new guidelines mandating centralized purchases for high-value medical consumables.

Author/ Professor Chris Trimble Explains Why Reverse Innovation Is “Oxygen,” Not Optional For MNCs: An Interview With PharmAsia News (Part 1 Of 2)

Authors Chris Trimble and Vijay Govindarajan, professors at The Tuck School of Business at Dartmouth, coined the term ‘reverse innovation’ and recently published a book arguing why MNCs need to incorporate RI systemically into their core competitive strategies. Below, Trimble speaks to PharmAsia News on the topic and how pharma companies can relate to it.

Reverse Innovation And Localization To Reduce Costs For Device Players: China Healthcare Investment Conference

Medtronic, Mindray and Lepu fill different niches, and executives discussed opportunities to build off of each other at a recent Shanghai conference.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel